Nirmatrelvir-ritonavir addition to acute care formulary: a retrospective, multi-centre evaluation of quantitative economic and qualitative clinical outcomes
Economic data from this study of elderly adults with mild-moderate COVID-19 suggest that addition of NMV/r to hospital formulary should be considered to support optimal resources consumption, while the clinical impact of NMV/r availability may be better studied through evaluating mild or moderate COVID-19 disease independently.
Authors
- Timothy P. Gauthier (ORCID: https://orcid.org/0000-0003-0700-703X)
- Erika Dittmar (ORCID: https://orcid.org/0000-0002-6634-1364)
- Lourdes R Menendez Alvarado (ORCID: https://orcid.org/0009-0009-0631-6261)
- Jefferson Cua (ORCID: https://orcid.org/0009-0009-5863-9935)
- José Ledesma
Institutions
- Baptist Hospital of Miami (US)
- Baptist Health South Florida (US)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-11-25
- DOI
- https://doi.org/10.1093/jac/dkaf448
- Primary Topic
- SARS-CoV-2 and COVID-19 Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00